Novakand Pharma Pivots to Orphan Drug Development for Treatment-Resistant Ovarian Cancer and Leukemia
核心洞察
Novakand Pharma (搜索) is shifting its drug development strategy from cardiovascular diseases to treatment-resistant ovarian cancer (搜索) and leukemia (搜索), conditions that currently lack adequate treatment options.
The strategic pivot is backed by shareholder support at the May 2026 Annual General Meeting and results from the company's Phase IIa "Kandova" clinical trial.
The drug candidates rugocrixan (搜索) and fosrugocrixan (搜索) act by blocking DNA repair within tumors, enhancing the effect of platinum-based chemotherapy and forcing cancer cells into programmed cell death.
Novakand Pharma (搜索) (Novakand) announced that its newly appointed Board of Directors is shifting the company's drug development strategy away from cardiovascular diseases and toward treatment-resistant ovarian cancer (搜索) and leukemia (搜索)—conditions that currently lack adequate treatment options. The strategic pivot is backed by strong support from shareholders at the May 2026 Annual General Meeting, the new board, the company's network of clinical oncologists, and results from Novakand's latest Phase IIa clinical trial, "Kandova."
These particularly vulnerable patients represent subgroups within ovarian cancer (搜索) and leukemia (搜索) that qualify for orphan drug designation. Upon future approval of Novakand's drug candidates as orphan drugs, regulatory authorities in both the US and Europe offer extended exclusive marketing protection for seven and ten years, respectively.
A New Strategy to Overcome Treatment Resistance
Novakand's new focus resolves several challenges that previously prevented effective development of the company's drug candidates. The advantages of this direction include the potential for extended market protection at lower development costs, leading up to a commercially attractive partnership with an internationally established pharmaceutical company.
Scientifically, the strategy relies on the drug candidates rugocrixan (搜索) and fosrugocrixan (搜索) (hereafter "rugocrixan") acting as a monotherapy or in combination with established drugs to prevent cancer cells from repairing themselves, thereby forcing them into programmed cell death. At the cellular level, this effect has been shown to be linked to rugocrixan blocking DNA repair within the tumor, which enhances the intended effect of platinum-based chemotherapy.
Consequently, this future treatment could cause tumor regression, reduce the number of cancer cells in the blood, and put the disease into retreat. The mechanism is supported by published research demonstrating that targeting CX3CR1 (搜索) suppresses the Fanconi Anemia DNA repair pathway and synergizes with platinum, as well as findings that a CX3CR1 (fractalkine receptor) small molecular antagonist (KAND567) suppressed the growth-promoting effect of monocytes on chronic lymphocytic leukemia (搜索) cells.
Furthermore, results from the company's clinical study "Kandova" show that it is possible to identify which patients are expected to benefit most from rugocrixan (搜索). This holds significant value—primarily medically for the patients, but also commercially for the company.
Execution Plan Toward a 2028 Pivotal Trial
To ensure time-efficient and thorough preparation before launching the commercially critical Phase II clinical trial in 2028, Novakand is currently focusing on several areas. These include determining which patient subgroup benefits most from rugocrixan (搜索) and which other drugs it should be combined with for maximum efficacy; calculating the treatment's market potential based on health benefits, competition, and willingness to pay among regulatory authorities and insurance companies; applying for orphan drug designation; designing the clinical trial and assembling a network of medical researchers and hospitals; and manufacturing the active substance rugocrixan and formulating capsules for the clinical trial.
The subsequent step involves running the Phase II clinical trial alongside the company's network of specialized clinics, with the goal of achieving the results necessary to build an attractive commercial partnership.
Financing and Corporate Context
To meet the timeline of starting the trial in 2028, additional capital is required. This fundraising will take place in two steps: a rights issue early in Q4 2026, and a subsequent share issue in 2027, the structure of which is yet to be determined. Details regarding the rights issue will be presented in September/October in connection with an Extraordinary General Meeting (EGM). A rights issue means that existing shareholders have preferential rights to purchase the new shares.
The strategic shift follows a period of corporate transition. Nasdaq delisted the company in April 2026 after a failed acquisition and lack of qualifying operations, with a new board and management subsequently appointed. For H1 2026, net sales remained at SEK 0.0 million, while R&D expenses decreased sharply to SEK 2.5 million (15.8) year-over-year. Operating loss improved to SEK -6.3 million (-19.5) compared to H1 2025, and cash at period end stood at SEK 9.0 million (27.6).
"Altogether, Novakand's promising results for rugocrixan (搜索) have attracted a new Board and an emerging new management team. With great humility and energy, we are taking on the task of transforming promising research into clinical proof that we can actually fight tumors. We look forward to achieving this goal in close collaboration with patient groups, specialist physicians, leading researchers, and our dedicated shareholders—both existing and future ones," said Michael Zell, Chairman of the Board, Novakand Pharma (搜索) AB.
Novakand Pharma (搜索) is a clinical-stage biotechnology company developing a new class of small-molecule drugs with a cancer- and immune-cell-modulating mechanism of action targeting orphan indications. The company is currently not listed on any stock exchange.